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Abstract
Background:  Sotos syndrome is an overgrowth syndrome characterized by macrocephaly,
advanced bone age, characteristic facial features, and learning disabilities, caused by mutations or
deletions of the NSD1 gene, located at 5q35. Sotos syndrome has been described in a number of
patients with autism spectrum disorders, suggesting that NSD1 could be involved in other cases of
autism and macrocephaly.
Methods: We screened the NSD1 gene for mutations and deletions in 88 patients with autism
spectrum disorders and macrocephaly (head circumference 2 standard deviations or more above
the mean). Mutation analysis was performed by direct sequencing of all exons and flanking regions.
Dosage analysis of NSD1 was carried out using multiplex ligation-dependent probe amplification.
Results: We identified three missense variants (R604L, S822C and E1499G) in one patient each,
but none is within a functional domain. In addition, segregation analysis showed that all variants
were inherited from healthy parents and in two cases were also present in unaffected siblings,
indicating that they are probably nonpathogenic. No partial or whole gene deletions/duplications
were observed.
Conclusion:  Our findings suggest that Sotos syndrome is a rare cause of autism spectrum
disorders and that screening for NSD1  mutations and deletions in patients with autism and
macrocephaly is not warranted in the absence of other features of Sotos syndrome.
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Background
Sotos syndrome (MIM 117550) is a childhood over-
growth syndrome characterized by distinctive facial fea-
tures including prominent forehead, down-slanted
palpebral fissures and pointed chin, macrocephaly and
learning disabilities. Sotos syndrome is caused by hap-
loinsufficiency of the NSD1 (nuclear receptor binding SET
domain protein 1) gene [1], which encodes a coregulator
of nuclear receptors that can activate or repress transcrip-
tion [2]. Point mutations are identified in the majority of
non-Japanese patients with Sotos syndrome (~80%),
whereas 5q35 microdeletions encompassing NSD1  are
the major cause among Japanese patients (>50%) [3,4].
Most cases of Sotos syndrome are sporadic, but occasional
familial cases have been reported, with dominant inherit-
ance. Affected children usually exhibit developmental
delay, and speech delay is common. In addition, autism
spectrum disorders or autistic features have been
described in a number of patients with Sotos syndrome
[5-13].
Autism is a behaviorally defined neurodevelopmental
syndrome characterized by social and communication
deficits, and the presence of restricted and repetitive
behaviors and interests, with onset in the first three years
of life. Recent epidemiological studies indicate that
autism is a common disorder, affecting as many as 2 in
1000 children [14]. The prevalence of all autism spectrum
disorders, which include autism, pervasive developmental
disorder not otherwise specified (PDD-NOS) and
Asperger syndrome, is estimated at 6 per 1000 [14].
Autism is approximately four times more frequent in
males than in females. Family and twin studies have
shown that genetic factors play a major role in the suscep-
tibility to autism [15] but genetic heterogeneity has made
the identification of the genes involved difficult [16].
Monogenic disorders such as fragile X syndrome and
other forms of X-linked mental retardation, tuberous scle-
rosis complex, neurofibromatosis, and various rare meta-
bolic disorders are identified in a small percentage of
patients [17]. Cytogenetically visible chromosomal aber-
rations are identified in approximately 5% of affected
individuals [10], while recent higher-resolution whole-
genome analyses using array-based technologies have
revealed genomic imbalances in at least 10% of cases
[18,19]. However, the underlying cause remains
unknown in the majority of patients.
Autism is associated with macrocephaly in approximately
20% of cases [20,21]. Although macrocephaly is one of
the most widely replicated neurobiological findings in
autism, its pathogenesis remains unknown. The descrip-
tion of several cases of Sotos syndrome in patients with
autism and macrocephaly [5-13] suggests that NSD1
could be involved in other cases of autism. Thus, the aim
of this study was to assess the frequency of NSD1 muta-
tions in cases of autism spectrum disorder associated with
macrocephaly, defined as an occipitofrontal head circum-
ference (HC) 2 SD or more above the mean. We screened
NSD1 by direct sequencing in 88 subjects with autism
spectrum disorder and macrocephaly. In addition, we
searched for deletions of the NSD1 gene using multiplex
ligation-dependent probe amplification (MLPA). Our
results showed no point mutations or deletions of NSD1,
indicating that Sotos syndrome is a rare cause of autism
spectrum disorders with macrocephaly.
Methods
Patients
A total of 88 patients with an autism spectrum disorder
and macrocephaly (HC ≥+2 SD) were included in the
study. Among these, 49 were recruited by the Paris Autism
Research International Sibpair (PARIS) study at special-
ized clinical centers in France, Sweden, Norway, Italy, Bel-
gium, Austria, and the United States, and 39 were
collected at the Mount Sinai School of Medicine and/or
the Autism Genetic Resource Exchange (AGRE) [22].
Patients were identified from a larger pool of 462 families
for which head circumference measures were available. All
patients with a HC ≥+2 SD were included in the study; in
families with two or more siblings with an autism spec-
trum disorder and macrocephaly, one individual was cho-
sen at random for the mutation screening.
The patients from the PARIS study included 45 males and
4 females from 16 multiplex families (with two or more
affected siblings) and 33 simplex families (sporadic
cases), with a mean age at the last evaluation of 10.5 ± 5.8
years (range 3.5–26). All patients were evaluated by expe-
rienced psychiatrists or child neurologists; diagnoses were
based on clinical evaluation and DSM-IV and ICD-10 cri-
teria. In addition, patients with autistic disorder were
assessed with the Autism Diagnostic Interview-Revised
(ADI-R) [23] and those with Asperger syndrome were
assessed with the Asperger Syndrome Diagnostic Inter-
view (ASDI) [24]. Forty-five individuals met criteria for
autistic disorder, 2 for PDD-NOS and 2 for Asperger syn-
drome. There were 35 patients with mental retardation
and 22 with limited or no language. Laboratory tests to
rule-out medical causes of autism included standard kary-
otyping, fragile X testing, and metabolic screening; brain
imaging and EEG were performed when possible. Patients
diagnosed with medical disorders such as fragile X syn-
drome or chromosomal abnormalities were excluded
from the study. There were 41 individuals of Caucasian
origin, 2 Black, 1 Asian and 5 of mixed ethnicity. The
study was approved by the research ethics boards of the
collaborating institutions. Informed consent was
obtained from all families participating in the study.BMC Medical Genetics 2007, 8:68 http://www.biomedcentral.com/1471-2350/8/68
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Thirty-nine patients were recruited by the Seaver Autism
Research Center (SARC) at Mount Sinai, New York, co-
recruited by the SARC and AGRE, or obtained from AGRE.
The patients included 31 males and 8 females from 35
multiplex families and 4 simplex families, with a mean
age at the last evaluation of 10.5 ± 4.2 years (range 5–24).
The ADI-R was used to assess affected subjects. There were
35 individuals with autism, 1 with borderline autism, 2
with Asperger syndrome and 1 with PDD-NOS. The term
'borderline autism' (or 'not quite autism') refers to indi-
viduals who are no more than one point away from meet-
ing autism criteria according to the ADI-R on any or all of
the 3 main domains of autistic impairment – social, com-
munication, and repetitive behavior – and meet the age of
onset criterion (before 36 months); or individuals who
meet criteria on all 3 domains but do not meet the age of
onset criterion. Seventeen patients had mental retardation
and 16 had limited or no language. Subjects with co-mor-
bid genetic disorders (fragile X syndrome, tuberous sclero-
sis, or chromosomal anomalies) were excluded. There
were 32 individuals of Caucasian origin, 1 Black, 1 Asian,
and 5 of mixed or unknown ethnicity. All parents pro-
vided written informed consent. The study was approved
by the local institutional review board.
HC among the 88 subjects included in the study ranged
from +2 to +9.6 SD for age and sex. There were 68 subjects
with a HC between +2 and +2.9 SD, 18 with a HC between
+3 and +4 SD, and only 2 subjects with a HC greater than
+4 SD. The patient with the largest HC (+9.6 SD) among
all the study subjects was later found to have a PTEN
mutation [25].
NSD1 mutation analyses
The NSD1 gene consists of 23 exons, the first of which is
non coding. All exons (including exon 1), intron-exon
boundaries and flanking intronic sequences were ana-
lyzed for mutations by direct sequencing of forward and
reverse strands. When variants not described previously
were detected, the DNA of parents and unaffected siblings
(when available) was analyzed by direct sequencing for
the specific base change identified in the proband.
NSD1 microdeletion analyses
In order to identify microdeletions of the NSD1 gene we
performed MLPA [26] using a commercially available kit,
according to the manufacturer's protocol (SALSA P026B
Sotos; MRC-Holland, Amsterdam, The Netherlands). The
P026B probe set contains 24 NSD1 probes, including one
probe in the promoter region (1 Kb 5' of exon 1) and one
probe for each of the 23 exons. The kit also contains six
probes for five neighboring genes on 5q31-35 (IL4, IL12B,
FGFR4, FLT4 and TRIM52), as well as 12 control probes in
other chromosomes. Electrophoresis of PCR products was
performed on an ABI 3730 sequencing platform (Applied
Biosystems, Foster City, CA, USA) and the resultant traces
were analyzed using the software GeneMarker (SoftGenet-
ics, State College, PA, USA).
Results
NSD1 mutation analyses
Genomic DNA from 88 unrelated individuals with autism
spectrum disorders and macrocephaly was screened for
intragenic NSD1 mutations by sequencing analysis. No
frameshift or nonsense mutations were identified in any
sample. Three missense variants, R604L, S822C and
E1499G, were each identified in one individual (Table 1).
R604L, in exon 5, was described previously in one patient
referred for genetic testing of Sotos syndrome, and was
classified as a variant of unknown significance [27].
S822C, also in exon 5, and E1499G in exon 10, have not
been described previously. None of these variants is in a
known functional domain of the protein [28]. Segrega-
tion analysis showed that all three variants were inherited
from reportedly healthy parents and in two cases were
present also in unaffected siblings, indicating that they are
likely nonpathogenic. Furthermore, we identified two
synonymous variants and two intronic substitutions
present in one patient each, which were also inherited
from unaffected parents. Table 1 shows all the sequence
changes identified in our patients, including several new
polymorphisms identified in this study.
NSD1 microdeletion analyses
There was no evidence for partial or whole gene deletions
or duplications of the NSD1 gene in any of the patients
screened with MLPA.
Discussion
Screening of the NSD1 gene in a cohort of 88 familial and
sporadic cases of autism and macrocephaly did not reveal
any intragenic mutations or deletions, indicating that
Sotos syndrome is a rare cause of autism spectrum disor-
ders. The three missense variants identified in one indi-
vidual each (R604L, S822C and E1499G), were inherited
from unaffected parents, suggesting that they are likely to
be polymorphisms. In addition, none of these variants is
located in a known functional domain [28], further sug-
gesting that they are nonpathogenic. Previous studies
have shown that missense mutations are pathogenic only
if they occur within functional domains of the protein
involved in chromatin regulation [4].
Our negative findings are in agreement with recent studies
showing that virtually all patients with a NSD1 mutation
or deletion have the characteristic facial features of Sotos
syndrome (broad forehead, sparse frontotemporal hair,
long narrow face, malar flushing, down-slanted palpebral
fissures, prominent jaw, pointed chin) [4,29,30]. How-
ever, the facial features are subtle and are difficult to rec-BMC Medical Genetics 2007, 8:68 http://www.biomedcentral.com/1471-2350/8/68
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ognize by clinicians with limited experience with this
condition. The patients in our study presumably did not
have the facial gestalt of Sotos syndrome, although most
had not been evaluated by a clinical geneticist and it is
likely that the psychiatrists that evaluated the patients
were not all familiar with Sotos syndrome because of the
relative rarity of this condition.
The other key clinical features of Sotos syndrome are the
macrocephaly and the developmental delay. HC and
height are increased in the majority of children with Sotos
syndrome. By adulthood, height may fall within normal
limits, but macrocephaly usually persists. However, recent
studies have shown that HC and height are normal in
10% of NSD1 mutation-positive patients, indicating that
overgrowth, previously considered as a major criterion of
the disorder, is not necessary for the diagnosis of Sotos
syndrome [4].
Our series included a high proportion of familial cases of
autism spectrum disorders, as compared to singletons (51
vs. 37). Because Sotos syndrome is mostly a sporadic dis-
order, this could have contributed to the negative results
of this study. However, several familial cases of Sotos syn-
drome with NSD1 mutations have been described in the
past years [4,27,30-35], suggesting that familial, usually
milder, forms of the disorder might be underdiagnosed.
Besides Sotos syndrome, there are several other syn-
dromes presenting with macrocephaly and developmen-
tal delay, which are sometimes associated with autism.
Among the better known is the fragile X syndrome, which
is the most frequent genetic disorder identified in patients
with autism spectrum disorders, accounting for about 2%
of cases [36]. Molecular analysis for fragile X is routinely
performed in patients with autism and mental retarda-
tion, and was ruled out in the patients participating in our
study. Another disorder associated with autism and mac-
rocephaly is the PTEN  hamartoma tumor syndrome,
which includes Cowden syndrome and Bannayan-Riley-
Ruvalcaba syndrome. The PTEN gene has recently been
found to be mutated in several children with autism spec-
trum disorders and macrocephaly [37-40]. We screened
PTEN for mutations and deletions in the 88 individuals
with autism spectrum disorders and macrocephaly
reported in this study and identified one patient with
extreme macrocephaly carrying a de novo missense muta-
tion [25].
Table 1: Sequence variants identified in the NSD1 gene in 88 patients with autism spectrum disorders and macrocephaly
Location and Nucleotide Change Protein Change Frequency Inheritance Previously described1
Intron 1
IVS1+6T→C ... 1 T/C Paternal No
Exon 2
c.339C→T C113C 1 T/T Paternal/maternal, present in 1 sib with autism and 1 
unaffected sib
[27, 33]
Exon 5
c.1482C→T C494C 38 C/T, 2 T/T rs1363405
c.1811G→T R604L 1 G/T Paternal (no siblings) [27]
c.1749G→A E583E 19 G/A, 1 A/A rs3733874
c.1792T→C L598L 3 T/C rs28932176
c.840G→T V614L 19 G/T, 1 T/T rs3733875
c.2071G→A A691T 5 G/A rs28932177
c.2176T→C S726P 22 T/C, 2 C/C rs28932178
c.2465C→G S822C 1 C/G Maternal, present in 1 unaffected sib No
c.2835T→C S945S 1 T/C Maternal (absent in 1 sib with autism) No
c.3106G→C A1036P 5 G/C rs28932179
c.3705T→C N1235N 13 T/C rs28932181
Exon 10
c.4496A→G E1499G 1 A/G Paternal, present in 1 unaffected sib No
Intron 14
IVS14-45C→G ... 1 C/G Maternal, present in 1 unaffected sib No
Intron 17
IVS17-22G→A ... 16 G/A [51, 52]
Exon 23
c.6750G→A M2250I 16 G/A rs35848863
c.6782T→C M2261T 16 T/C rs34165241
c.6829C→T L2277L 19 C/T, 1 T/T rs28580074
c.6903G→C G2301G 29 G/C, 4 C/C rs11740250
c.7636G→A A2546T 11 G/A [32, 52]
1 References are given only for variants without a RefSNP accession ID (rs number)BMC Medical Genetics 2007, 8:68 http://www.biomedcentral.com/1471-2350/8/68
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Other examples of disorders associated with macroceph-
aly which carry an increased risk for the development of
autism include neurofibromatosis type I [41,42] and
22q13 deletions [43]. In addition, there are several reports
in the literature of cases with progressive postnatal macro-
cephaly with autism, marked speech delay and mental
retardation, referred to as the Cole-Hughes macrocephaly
syndrome [44,45]. The Orstavik syndrome, described by
Orstavik et al. [46], is characterized by macrocephaly, epi-
lepsy, autism, mental retardation and dysmorphic fea-
tures. Several other cases of the same syndrome were
reported later by another group [47]. As Sotos syndrome,
these disorders account for only a small number of
patients with autism and macrocephaly.
The macrocephaly observed in about 20% of patients with
autism appears to be an independent clinical trait, not
related to sex, presence of morphological abnormalities,
IQ, occurrence of seizures, or severity of autistic symp-
toms [20,21]. Converging evidence from HC measure-
ments, MRI studies and postmortem brain weight
indicates that an even greater proportion of children with
autism have an abnormal regulation of brain growth,
resulting in enlarged brains during early childhood [48].
At birth, HC is typically normal or slightly reduced, fol-
lowed by accelerated growth during the first years of life.
This early phase of excessive growth is followed by slowed
growth after 2–4 years of age, so that in adolescents and
adults HC measures are usually within normal range [48].
Other studies, however, have found increased brain vol-
ume in older populations of individuals with autism
[49,50], so the timing of brain enlargement is not settled
yet. Similarly, the pattern of enlargement across the brain
lobes and cerebellum and the involvement of gray versus
white matter remain unclear at present. Elucidation of the
mechanisms involved in the pathological postnatal brain
overgrowth may prove critical for understanding the
emergence of autistic symptoms during the same time
frame.
Conclusion
In conclusion, no NSD1 mutations, 5q35 microdeletions
or partial NSD1  deletions were identified in this large
sample of patients with autism spectrum disorders and
macrocephaly. Our results suggest that Sotos syndrome is
a rare cause of autism spectrum disorders and that screen-
ing for NSD1 mutations and deletions in patients with
autism and macrocephaly is not warranted in the absence
of other features of Sotos syndrome.
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